Antibody treatment of human tumor xenografts elicits active anti-tumor immunity in nude mice

Immunology Letters

Volumn 114, Issue 1, 2007, Pages 16-22

  Liebman, Meredith A ^a   Roche, Marly I ^b   Williams, Brent R ^a   Kim, Jae ^a   Pageau, Steven C ^a   Sharon, Jacqueline ^a  

^a Hubert H Humphrey Cancer Research Center   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive transfer; Antibodies; Nude mice; Spleen cells; SW480 human tumor cell line; T Cells; Tumor immunity

Indexed keywords

CANCER ANTIBODY; EDRECOLOMAB; POLYCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; EXPERIMENTAL STUDY; FEMALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; THYMUS; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR REJECTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 35448996465     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.08.006     Document Type: Article

References (20)

1. Lake J.P., Pierce C.W., and Kennedy J.D. T cell receptor expression by T cells that mature extrathymically in nude mice. Cell Immunol 135 (1991) 259-265
2. Kennedy J.D., Pierce C.W., and Lake J.P. Extrathymic T cell maturation. Phenotypic analysis of T cell subsets in nude mice as a function of age. J Immunol 148 (1992) 1620-1629
3. Ferrick D.A., Sambhara S.R., Chadwick B.S., Miller R.G., and Mak T.W. The T-cell receptor repertoire is strikingly similar in older nude mice compared to normal adult mice. Thymus 13 (1989) 103-111
4. Chen W.F., Scollay R., Shortman K., Skinner M., and Marbrook J. T-cell development in the absence of a thymus: the number, the phenotype, and the functional capacity of T lymphocytes in nude mice. Am J Anat 170 (1984) 339-347
5. Bubenik J., Kieler J., Jandlova T., and Simova J. Age-related decrease in transplantability of human tumours in nu/nu mice. Anticancer Res 12 (1992) 1695-1698
6. Li Y., Newby S.A., Johnston J.V., Hellstrom K.E., and Chen L. Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice. J Immunol 155 (1995) 5705-5710
7. Herlyn D.M., Steplewski Z., Herlyn M.F., and Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 40 (1980) 717-721
8. Mokbel K., and Hassanally D. From HER2 to herceptin. Curr Med Res Opin 17 (2001) 51-59
9. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 (2005) 671-680
10. Shulman M., Wilde C.D., and Kohler G. A better cell line for making hybridomas secreting specific antibodies. Nature 276 (1978) 269-270
11. Liebman M.A., Williams B.R., Daley K.M., and Sharon J. Generation and preliminary characterization of an antibody library with preferential reactivity to human colorectal cancer cells as compared to normal human blood cells. Immunol Lett 91 (2004) 179-188
12. Williams B.R., and Sharon J. Polyclonal anti-colorectal cancer Fab phage display library selected in one round using density gradient centrifugation to separate antigen-bound and free phage. Immunol Lett 81 (2002) 141-148
13. Fogh J., Fogh J.M., and Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59 (1977) 221-226
14. Herlyn M., Steplewski Z., Herlyn D., and Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76 (1979) 1438-1442
15. Krawczyk C.M., Verstovsek S., Ujhazy P., Maccubbin D., and Ehrke M.J. Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother 40 (1995) 347-357
16. Ehrke M.J., Verstovsek S., Krawczyk C.M., Ujhazy P., Zaleskis G., Maccubbin D.L., et al. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer 63 (1995) 463-471
17. Ehrke M.J., Verstovsek S., Zaleskis G., Ho R.L., Ujhazy P., Maccubbin D.L., et al. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother 42 (1996) 221-230
18. Ehrke M.J., Verstovsek S., Pocchiari S.K., Krawczyk C.M., Ujhazy P., Zaleskis G., et al. Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer 76 (1998) 579-586
19. Ehrke M.J., Verstovsek S., Ujhazy P., Meer J.M., Eppolito C., Maccubbin D.L., et al. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother 45 (1998) 287-298
20. Ehrke M.J., Verstovsek S., Maccubbin D.L., Ujhazy P., Zaleskis G., Berleth E., et al. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer 87 (2000) 101-109